Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
0.6096
Dollar change
-0.0040
Percentage change
-0.65
%
Index- P/E- EPS (ttm)-0.42 Insider Own1.86% Shs Outstand192.42M Perf Week4.47%
Market Cap117.26M Forward P/E- EPS next Y-0.56 Insider Trans0.47% Shs Float188.78M Perf Month-11.58%
Income-79.51M PEG- EPS next Q-0.22 Inst Own17.81% Short Float0.28% Perf Quarter-27.34%
Sales0.00M P/S- EPS this Y-21.49% Inst Trans22.47% Short Ratio6.61 Perf Half Y-23.80%
Book/sh0.58 P/B1.05 EPS next Y38.81% ROA-41.98% Short Interest0.52M Perf Year-67.75%
Cash/sh0.53 P/C1.15 EPS next 5Y21.22% ROE-54.69% 52W Range0.42 - 2.26 Perf YTD-36.02%
Dividend Est.- P/FCF- EPS past 5Y35.36% ROI-67.13% 52W High-73.03% Beta0.70
Dividend TTM- Quick Ratio4.51 Sales past 5Y0.00% Gross Margin- 52W Low45.14% ATR (14)0.06
Dividend Ex-Date- Current Ratio4.51 EPS Y/Y TTM28.86% Oper. Margin0.00% RSI (14)43.90 Volatility7.12% 11.05%
Employees104 Debt/Eq0.11 Sales Y/Y TTM- Profit Margin- Recom1.80 Target Price2.28
Option/ShortYes / Yes LT Debt/Eq0.06 EPS Q/Q-29.98% Payout- Rel Volume0.94 Prev Close0.61
Sales Surprise-37.99% EPS Surprise-33.33% Sales Q/Q- EarningsMay 07 AMC Avg Volume78.90K Price0.61
SMA20-3.28% SMA50-12.36% SMA200-37.33% Trades Volume74,032 Change-0.65%
Date Action Analyst Rating Change Price Target Change
Jan-04-23Upgrade Societe Generale Hold → Buy
Dec-16-22Downgrade Goldman Neutral → Sell
May-10-22Downgrade Goldman Buy → Neutral $6 → $1.50
Sep-14-21Upgrade Societe Generale Hold → Buy
Jan-22-21Downgrade Societe Generale Hold → Sell
Nov-02-20Upgrade Societe Generale Sell → Hold
Aug-06-20Downgrade Societe Generale Buy → Sell
Aug-05-20Reiterated H.C. Wainwright Buy $25 → $14
Mar-17-20Downgrade Stifel Buy → Hold $18 → $6
Jan-09-20Upgrade Stifel Hold → Buy $10 → $18
May-17-24 04:30PM
May-16-24 04:30PM
May-09-24 04:30PM
May-07-24 11:53PM
04:30PM
04:30PM Loading…
Apr-25-24 04:30PM
Apr-04-24 04:43PM
Mar-08-24 11:01AM
09:33AM
Mar-07-24 10:52PM
04:30PM
Mar-04-24 04:30PM
Feb-20-24 04:30PM
Jan-16-24 04:30PM
Dec-04-23 04:30PM
04:30PM Loading…
Nov-09-23 04:30PM
Nov-06-23 04:30PM
Nov-02-23 04:30PM
Oct-31-23 04:30PM
Oct-27-23 04:30PM
Oct-16-23 02:00AM
Oct-05-23 04:30PM
Sep-05-23 04:30PM
Jul-31-23 04:25PM
Jul-25-23 04:30PM
Jul-19-23 04:30PM
Jul-10-23 04:30PM
Jun-16-23 04:30PM
Jun-08-23 04:30PM
Jun-06-23 05:00PM
05:30PM Loading…
May-10-23 05:30PM
May-09-23 04:30PM
May-04-23 04:30PM
Apr-19-23 05:09PM
Apr-12-23 04:30PM
Mar-24-23 04:30PM
Mar-13-23 01:30AM
Mar-07-23 04:30PM
Mar-02-23 05:30PM
04:30PM
Feb-27-23 01:30AM
Feb-21-23 04:30PM
Feb-10-23 04:30PM
Jan-23-23 04:30PM
Jan-04-23 04:30PM
Dec-23-22 01:30AM
Dec-08-22 04:30PM
Nov-22-22 04:30PM
Nov-09-22 01:30AM
Nov-03-22 04:30PM
Oct-31-22 04:30PM
Oct-20-22 04:30PM
Oct-03-22 04:30PM
Sep-21-22 05:45PM
Sep-07-22 04:30PM
Sep-02-22 04:30PM
Aug-10-22 04:50PM
Aug-01-22 04:30PM
Jul-27-22 04:30PM
Jul-20-22 04:30PM
Jun-28-22 06:15PM
Jun-16-22 01:30AM
Jun-09-22 02:55AM
Jun-07-22 04:30PM
May-17-22 04:30PM
May-12-22 04:30PM
May-04-22 07:30PM
May-02-22 05:00PM
04:00PM
Apr-25-22 07:30PM
04:30PM
Apr-21-22 04:30PM
Apr-14-22 04:30PM
Mar-14-22 04:30PM
Mar-11-22 04:30PM
Mar-09-22 04:30PM
Mar-03-22 04:15PM
Feb-24-22 04:30PM
Feb-22-22 04:30PM
Feb-14-22 04:30PM
Feb-09-22 04:30PM
Jan-21-22 04:30PM
Jan-18-22 05:38PM
01:38PM
Jan-12-22 04:30PM
Jan-07-22 01:30AM
Dec-20-21 04:15PM
Dec-10-21 04:30PM
Nov-24-21 01:30AM
Nov-04-21 04:30PM
Nov-01-21 03:34PM
02:30AM
Oct-29-21 05:07PM
Oct-27-21 03:35PM
Oct-26-21 04:15PM
Oct-12-21 04:30PM
Sep-08-21 04:00PM
Aug-31-21 01:30AM
Aug-20-21 04:15PM
Aug-09-21 04:30PM
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stephane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tasse DanielCHIEF EXECUTIVE OFFICERMar 08 '24Buy0.8317,09414,18817,094Mar 11 04:15 PM
Ndu AdoraDirectorFeb 06 '24Buy0.891,8251,6241,825Feb 08 05:02 PM
Mohideen PharisChief Medical OfficerNov 22 '23Sale1.742,2453,90682,194Dec 19 04:44 PM
MORRIS TIMOTHY EDirectorAug 25 '23Buy1.5212,00018,24012,000Aug 28 04:35 PM
SOLAND DANIEL BDirectorAug 01 '23Buy1.6215,00024,30020,000Aug 03 04:40 PM